文献速递脑血管病神经重症与神经感染

房颤合并脑出血患者:NOAC与华法林的比较

Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage.
PubMed 文献 · Stroke · 2019-01-01

全国性观察队列研究纳入622例房颤合并脑出血后启用口服抗凝药的患者,比较NOAC与华法林1年缺血性卒中及再发脑出血风险。NOAC组缺血性卒中风险4.01%对华法林7.85%,加权风险比0.52(0.27-1.00);再发脑出血风险5.07%对7.00%,加权风险比0.72(0.38-1.38),差异均未达统计学显著。结论支持在此类患者中选择NOAC进行卒中预防。

要点

  • 房颤合并脑出血患者启用NOAC,1年缺血性卒中风险数值低于华法林但未达显著。
  • 再发脑出血风险NOAC组亦数值偏低,加权风险比0.72,置信区间跨1。
  • 结果支持现有推荐:此类患者卒中预防可优先选用NOAC。

核心结论

  • 与华法林相比,NOAC与房颤合并脑出血患者较低的缺血性卒中和再发脑出血风险相关,但差异未达统计学显著。
  • 结果支持当前推荐在此类患者中选择NOAC进行卒中预防。

研究设计与样本

  • 全国性观察性队列研究,纳入房颤合并脑出血后再次申领口服抗凝药处方的患者。
  • 共622例,274例申领华法林,348例申领NOAC;平均年龄76岁,女性39%。
  • 采用逆概率治疗加权绝对风险降低和风险比评估1年缺血性卒中与脑出血风险。

主要发现

  • 1年缺血性卒中风险:华法林7.85%,NOAC 4.01%;加权绝对风险降低3.78%(95%CI -0.15%至7.71%),加权风险比0.52(0.27-1.00)。
  • 再发脑出血风险:华法林7.00%,NOAC 5.07%;加权绝对风险降低1.93%(95%CI -2.02%至5.87%),加权风险比0.72(0.38-1.38)。
  • 72%的索引事件为非严重事件,28%为中重度事件(依据Scandinavian Stroke Severity量表)。

临床怎么用

  • 房颤合并脑出血患者启动抗凝时,可优先考虑NOAC而非华法林以降低缺血性卒中风险。
  • 决策需个体化,结合出血严重程度、复发风险及患者偏好综合评估。

局限性

  • 观察性设计可能存在残余混杂。
  • 样本量有限,置信区间较宽且跨1,不能排除无效或有害可能。
  • 仅纳入再次申领口服抗凝药处方的患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Recurrent bleeding associated with oral anticoagulants (OACs) causes a dilemma in patients with atrial fibrillation (AF) sustaining an intracerebral hemorrhage. Treatment recommendations guiding clinical practice on optimal OAC agent selection in this population are lacking. This study aimed to investigate the comparative effectiveness and safety of non-vitamin K antagonist OAC (NOAC) versus warfarin in patients with AF sustaining an intracerebral hemorrhage. Methods- We conducted a nationwide observational cohort study including patients with AF sustaining an intracerebral hemorrhage and who subsequently claimed an OAC prescription. Contrasts of 1-year risks for ischemic stroke and intracerebral hemorrhage risks were obtained and evaluated by inverse probability treatment weighted absolute risk reduction and risk ratios. Results- Among 622 AF patients with intracerebral hemorrhage, 274 claimed a warfarin prescription and 348 a NOAC prescription. Mean age was 76 years (39% females); 72% had an index nonsevere event and 28% moderate to severe index event according to the Scandinavian Stroke Severity scale. The 1-year ischemic stroke risk was 7.85% for warfarin and 4.01% for NOACs, with a weighted absolute risk reduction of 3.78% (95% CI, -0.15% to 7.71%); the weighted risk ratio was 0.52 (0.27-1.00). For recurrent intracerebral hemorrhage, the risk was 7.00% for warfarin and 5.07% for NOACs. The absolute risk reduction was 1.93% (-2.02% to 5.87%), with an a weighted risk ratio of 0.72 (0.38-1.38). Conclusions- NOACs were associated with a nonsignificant lower risk of ischemic stroke and recurrent intracerebral hemorrhage compared with warfarin. The results add to current recommendations of selecting a NOAC agent for stroke prophylaxis treatment in patients with AF, including those with sustaining an intracerebral hemorrhage.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Nielsen PB, Skjøth F, Søgaard M, et al. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. Stroke. 2019. PMID: 30869568. doi:10.1161/STROKEAHA.118.023797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。